NCT00270491已完成2 期
A Multicenter Randomized Phase II Study Evaluating Tolerance and Efficacy of Capecitabine 5/7 Days With Weekly Paclitaxel Versus the Recommended Treatment Plan of Weekly Paclitaxel-capecitabine, in Patients With Metastatic Breast Cancer.
ARCAGY/ GINECO GROUP2 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2005年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 130
- 试验地点
- 2
- 主要终点
- tolerance of the patients in the both groups.
研究概览
简要总结
Tolerance and efficacy of administration of capecitabine 5 out of 7 days associated with weekly paclitaxel compared to the recommended treatment plan of weekly paclitaxel - capecitabine, in patients with metastatic breast cancer.
详细描述
The purpose of this study is to know if we can optimize in term of tolerance even of efficacy the plan of administration of weekly paclitaxel associated with capecitabine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Femal patient aged > 18 years
- •Histologically proven breast adenocarcinoma
- •HER2 negative receptors
- •previously received first or second line chemotherapy for metastatic disease
- •previously treated with anthracycline and/or docetaxel in adjuvant and/or as first or second line therapy
- •presence of one or several evaluable metastatic lesion(s)
- •presence of at least one target lesion not previously irradiated
- •previously treated with hormonotherapy in adjuvant or in metastatic line (treatment will be ceased upon patient registration in the study)
- •ECOG Performance status < 2
- •adequate biological values
- •patient who has clearly given her consent by signing on informed consent form prior to participation
排除标准
- •patient previously treated with paclitaxel or capecitabine for metastatic breast cancer
- •patient with only local metastatic disease (with the exception of axillary lymph nodes)
- •active symptomatic brain metastasis
- •patient with an history of significant cardiovascular impairment (congestive heart failure> NYHA grade II, unstable angina or myocardial infraction within the past six months or serious cardiac arrhythmia)
- •peripheric neuropathy grade ≥ 2
- •history of another malignancy within past 5 years that could confound diagnosis or staging of breast cancer (with the exception of in situ cacinoma of the cervix or adequately treated basel cell carcinoma of the skin)
- •patient with any medical or psychiatric condition that, in the opinion of the Principal Investigator, would preclude her from participating in this study
- •patient with a known allergy to one or several of the study compounds
- •patients who may not be regularly available due to geographical, social or family reasons
- •history of renal, hepatic or metabolic pathology that could preclude with metabolism or elimination of the study product
- •deficiencies of the upper intestinal tract, malabsorption syndrome
- •patient who is pregnant, breast-feeding or using inadequate contraception
结局指标
主要结局
tolerance of the patients in the both groups.
次要结局
- - Response rates and duration of response.
- - Haematological and non-haematological toxicities.
- - Progression free survival.
- - Overall survival.
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days RegimenBreast NeoplasmsChemotherapyNCT00324610Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie46
已完成
2 期
Study of Irinotecan Plus Capecitabine to Treat Advanced Colorectal CancerColorectal CancerNCT01322152Fudan University52
已完成
2 期
Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard TherapyChronic Hepatitis CNCT00120861Merck Sharp & Dohme LLC
已完成
1 期
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)Solid TumorsOvarian CancerNCT00889382Astellas Pharma Inc152
已完成
2 期
Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer PatientsMetastatic Colorectal CancerNCT00875771Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)80